Zhodnocení účinnosti a rizik v léčbě roztroušené sklerózy
| Title in English | Evaluation of efficacy and risks in the treatment of multiple sclerosis |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| MU Faculty or unit | |
| Citation | |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | treatment of multiple sclerosis; efficacy; risks |
| Description | We use for the treatment of relapsing-remitting course of multiple sclerosis the drugs with different mechanisms of action anddifferent clinical efficacy and safety profile. The treatment algorithm involves current clinical status of the patient and long-termefficacy and safety of the drug. The available drugs are as following; interferon beta-1a (IFNbeta-1a), interferon beta-1b (IFNbeta-1b),glatiramer acetate(GA), teriflunomide, dimethylfumarate, fingolimode, natalizumab and alemtuzumab. |